AB
LXEO icon

Amalgamated Bank’s Lexeo Therapeutics LXEO Stock Holding History

Amalgamated Bank’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,982
Closed -$20K – 2307
2025
Q4 		$20K Buy
1,982
+1,359
+218% +$12.4K ﹤0.01% 2108
2025
Q3 		$4K Hold
623
– – ﹤0.01% 2845
2025
Q2 		$3K Hold
623
– – ﹤0.01% 2922
2025
Q1 		$2K Hold
623
– – ﹤0.01% 2853
2024
Q4 		$4K Hold
623
– – ﹤0.01% 2792
2024
Q3 		$6K Hold
623
– – ﹤0.01% 2706
2024
Q2 		$10K Hold
623
– – ﹤0.01% 2449
2024
Q1 		$10K Buy
+623
New +$9.74K ﹤0.01% 2449

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Bank's LXEO Position: Q1 2026 in Review

Amalgamated Bank sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 1,982 shares — an estimated $20K sold.

Amalgamated Bank first reported a position in LXEO in Q1 2024 and held it in 8 quarters. The position peaked at $20K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Amalgamated Bank reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,982 Lexeo Therapeutics shares in Q1 2026, an estimated $20K.
  • Amalgamated Bank first reported a position in Lexeo Therapeutics in Q1 2024 and held it in 8 quarters.
  • Amalgamated Bank's Lexeo Therapeutics position peaked at $20K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.